Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price fell 12.1% on Thursday . The stock traded as low as C$0.15 and last traded at C$0.15. 517,055 shares changed hands during trading, a decline of 38% from the average session volume of 834,902 shares. The stock had previously closed at C$0.17.
Hemostemix Price Performance
The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The company has a market capitalization of C$20.40 million, a P/E ratio of -4.08 and a beta of 0.20. The business’s fifty day moving average price is C$0.22 and its 200-day moving average price is C$0.13.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- Using the MarketBeat Stock Split Calculator
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- What is the FTSE 100 index?
- 3 Stocks to Buy While Others Stay on the Sidelines
- Which Wall Street Analysts are the Most Accurate?
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
